"Serving Families Affected By Opioid Misuse"
Keynote Speaker - Dr. Stephen Loyd
Important - You Must Register through the Virtual Course link here - you must complete this step to be registered for the Virtual only conference.
11:00am-11:15am - Lunch Pickup
11:15am-11:30am - Welcome
11:30am-11:45am - "Significance through a Personal Experience", Paris Hardee, BSN, RN
11:45am-12:00 pm- Break
12:00pm-12:20pm- "Responding to the Opioid Crisis", Alisa Haushalter, PhD, RN
12:20pm-1:15pm- "Addiction is not a Moral Failure", Stephen Loyd, MD
1:15pm-1:30pm - Break
1:30pm-2:30pm- "Addiction is not a Moral Failure" (continued), Stephen Loyd, MD
2:30pm-3:00pm- Questions and Evaluation
- There will be ample space for socially distanced learning.
- Room capacity is 500 and we are limiting to 50 in person attendees.
Keynote Speaker: Dr. Stephen Loyd, MD, FACP - CMO of JourneyPure, Associate Professor at ETSU and member of the governor’s subcabinet
Alisa Haushalter, DNP, RN- Director, Shelby County Health Department
Paris Hardee, BSN, RN
Successful Completion of this Nursing Professional Development Activity:
In order to receive full contact-hour credit for this NPD activity, you must:
Be in attendance for at least 80% of the program, and
Complete and submit the Evaluation and Verification of Attendance through the link provided at the conclusion of the program.
Requirements for successful completion may also include participation in individual or group activities, such as discussion, exercises, practice questions, pre-/post-testing, etc.
Conflicts of Interest: A Conflict of Interest occurs when an individual has an opportunity to affect educational content about health-care products or services of a commercial interest with which she/he has a financial relationship.
The planners and presenters of this NPD activity have disclosed no relevant financial relationships with any commercial interests pertaining to this activity.
Commercial Support: No
Noncommercial Sponsor Support: No
Off-label Product Use: This NPD activity does not include any unannounced information about off-label use of a product for a purpose other than that for which it was approved by the Food and Drug Administration (FDA).